Combination therapy is the direction this field keeps pointing, and the CagriSema evidence on weight is covered on this site’s sister publication. This trial put several combinations against their own components in liver disease, and the result runs the other way[1].
The primary endpoint was fibrosis improving by at least one stage without the underlying steatohepatitis worsening, at 52 weeks. Zalfermin 30 mg plus semaglutide achieved it in 24% against 16% on placebo — an estimated difference of 7.98 percentage points with a confidence interval from -3.82 to 19.79 and a p value of 0.19. That is the trial’s answer, and it is negative — the shape of result that rarely travels, unlike the positive findings catalogued in the liver disease evidence.
That said, the semaglutide figure needs its qualifier kept. The authors describe it as nominally significant, which means it was not the trial’s protected primary comparison and carries no multiplicity correction. In a seven-arm trial, one arm clearing p = 0.024 outside the primary hierarchy is a finding to test, not a result to bank — the same distinction that separates prespecified from post hoc analysis in the HFpEF sex analysis.
The screening funnel is worth noting for anyone reading trial results in this disease. Of 2,420 people screened, 178 withdrew and 1,544 were disqualified, leaving 698 randomized. Biopsy-confirmed MASH trials select very heavily, which is part of why their populations differ from the people actually prescribed these drugs — the gap examined in the approval and the fibrosis stage.
Adverse events were mostly non-serious and mild to moderate, dominated by gastrointestinal complaints, which is the familiar profile. What the trial contributes is a caution against assuming that stacking mechanisms stacks benefit — a question that also sits behind the liver mediation analysis and the myostatin blocker trial, where a second drug was added for a different purpose.